SSP

Update on SSPs for HRT preparations

Update on SSPs for HRT preparations

The Department of Health and Social Care (DHSC) has provided an update on the Serious Shortage Protocols (SSP) for Hormone Replacement Therapy preparations.

The following SSPs were previously expected to expire on Friday 19th August 2022 but the end date has been further extended to Friday 28th October 2022:

  • SSP019 Oestrogel 0.06% Pump-Pack Gel (RESTRICTION)
  • SSP020 Ovestin 1mg Cream (RESTRICTION)
  • SSP022 Oestrogel Pump-Pack 0.06% gel (SUBSTITUTION)
  • SSP023 Oestrogel Pump-Pack 0.06% gel (RESTRICTION AND SUBSTITUTION)
  • SSP024 Ovestin® 1mg cream (SUBSTITUTION)
  • SSP025 Ovestin® 1mg cream (RESTRICTION AND SUBSTITUTION)
  • SSP026 Lenzetto® 1.53mg/dose transdermal spray (RESTRICTION)
  • SSP027 Lenzetto® 1.53mg/dose transdermal spray (SUBSTITUTION)
  • SSP028 Lenzetto® 1.53mg/dose transdermal spray (RESTRICTION AND SUBSTITUTION)
  • SSP029 Sandrena® 0.5mg and 1mg gel sachets (RESTRICTION)
  • SSP030 Sandrena® 0.5mg and 1mg gel sachets (SUBSTITUTION)
  • SSP031 Sandrena® 0.5mg and 1mg gel sachets (RESTRICTION AND SUBSTITUTION)

The Department of Health and Social Care (DHSC) has confirmed that sufficient stock of Premique® low dose 0.3mg/1.5mg modified-release tablets is now available to meet normal demand. As a result the Serious Shortage Protocol, SSP021 Premique® low dose 0.3mg/1.5mg modified-release tablets expires at 23.59pm on Friday 29 July 2022. After this date, any prescriptions for Premique® low dose 0.3mg/1.5mg modified-release tablets must be dispensed in accordance with the prescription, and the SSP021 will no longer be valid for use.

This expiry date may be brought forward or extended, and the content may be amended throughout this period. Pharmacists should ensure they are using the current version of an SSP before supplying an alternative product.

Further details